Archive: September, 2017

 

 

Avita Medical and BARDA Execute a US$24.3m Contract Option

Valencia, CA, USA, Perth, Australia and London, United Kingdom, 21 September 2017 — Avita Medical (ASX: AVH), (OTCQX: AVMXY),  - link here a regenerative medicine company specializing in the treatment...

Read more about Avita Medical and BARDA Execute a US$24.3m Contract Option

Adherium Releases Next Generation Adherence Monitor, SmartTurbo Model 4, for AstraZeneca’s Turbuhaler

12 Sep 2017 - link here

Read more about Adherium Releases Next Generation Adherence Monitor, SmartTurbo Model 4, for AstraZeneca’s Turbuhaler

AmpliPhi Biosciences Announces First Intravenous Treatment of a Patient with AB-SA01 Targeting Staphylococcus aureus

A patient suffering from a life-threatening staphylococcal endocarditis received AB-SA01 under expanded access regulatory guidelines

Read more about AmpliPhi Biosciences Announces First Intravenous Treatment of a Patient with AB-SA01 Targeting Staphylococcus aureus

AmpliPhi Biosciences Announces Receipt of $2.0 Million R&D Tax Incentive

SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces that it has received a...

Read more about AmpliPhi Biosciences Announces Receipt of $2.0 Million R&D Tax Incentive

Adherium Receives FDA Clearance for Smartinhaler sensor for AstraZeneca's Symbicort inhaler

04 Sep 2017 - link here

Read more about Adherium Receives FDA Clearance for Smartinhaler sensor for AstraZeneca's Symbicort inhaler